Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine, Irinotecan, and Oxaliplatin in Advanced Colorectal Cancer
NCT00215982Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2004
- Primary completion
- Jul 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in metastatic colorectal cancer (mCRC), sponsored by Moffitt Cancer Center. Primary endpoint: Radiographic Response Rate at 12 months. Started Dec 2004; status: completed.
02
Drugs
capecitabineoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00215982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00215982.